FCGR3B and pancreatic adenocarcinoma: To further assess the clinical impact of the signature (Figure 3C) for myeloid subclusters, including macrophages, mast cells, CD14 monocytes, CD16 monocytes and DCs, we utilized an independent PAAD cohort from TCGA.